Valuation: AstraZeneca Pharma India Limited

Market Cap 163B 1.74B 1.55B 1.43B 1.29B 2.45B 2.51B 17.07B 6.8B 87.16B 6.52B 6.38B 275B P/E 2025
186x
P/E 2026 103x
Enterprise Value 159B 1.7B 1.52B 1.4B 1.27B 2.4B 2.46B 16.71B 6.66B 85.36B 6.38B 6.25B 269B EV / Sales 2025
12.2x
EV / Sales 2026 8.38x
Free-Float
19.52%
Yield 2025
0.37%
Yield 2026 0.46%
1 day+0.50%
1 week+2.27%
Current month+2.27%
1 month+14.17%
3 months-20.47%
6 months-23.29%
Current year-27.72%
1 week 6,205
Extreme 6205
6,800
1 month 5,800
Extreme 5800
6,800
Current year 5,660
Extreme 5660
9,219.25
1 year 5,660
Extreme 5660
9,449
3 years 4,050.15
Extreme 4050.15
10,653.05
5 years 2,437.75
Extreme 2437.75
10,653.05
10 years 882.55
Extreme 882.55
10,653.05
Manager TitleAgeSince
Chief Executive Officer - 01/07/2025
Compliance Officer - 23/02/2026
Chief Tech/Sci/R&D Officer - 03/03/2025
Director TitleAgeSince
Director/Board Member 67 02/12/2016
Chairman 53 30/09/2024
Director/Board Member - 09/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
+0.50%+2.27%-28.27%+35.96% 1.72B
+2.43%+0.31%+46.42%+139.35% 1,206B
+1.92%+4.20%+49.63%+91.24% 665B
+0.70%+1.42%+33.94%+112.22% 515B
+2.77%-0.57%+49.44%+68.42% 381B
+1.03%-0.06%+70.92%+44.82% 362B
+0.29%-0.24%+30.84%+57.23% 307B
+0.98%+0.76%+9.04%+38.31% 289B
+1.01%-0.03%+43.77%+76.22% 249B
+1.47%-0.23%+43.83%+126.64% 207B
Average +1.22%-1.35%+34.96%+79.04% 418.15B
Weighted average by Cap. +1.57%-1.96%+43.75%+96.29%

Financials

2025 2026
Net sales 17.16B 183M 163M 150M 136M 259M 265M 1.8B 717M 9.19B 687M 673M 28.94B 22.76B 243M 217M 199M 181M 343M 351M 2.39B 951M 12.18B 911M 892M 38.37B
Net income 1.16B 12.35M 11.02M 10.14M 9.2M 17.44M 17.88M 121M 48.36M 620M 46.35M 45.35M 1.95B 1.88B 20.01M 17.86M 16.43M 14.91M 28.26M 28.96M 197M 78.35M 1B 75.09M 73.48M 3.16B
Net Debt -5B -53.39M -47.65M -43.85M -39.8M -75.42M -77.29M -525M -209M -2.68B -200M -196M -8.44B -3.37B -35.96M -32.1M -29.54M -26.81M -50.8M -52.06M -353M -141M -1.8B -135M -132M -5.68B
Projected Income Statement - Annual - AstraZeneca Pharma India Limited
Logo AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Employees
760
Date Price Change Volume
09/11/26 ₹6,512.20 +0.50% 545
08/11/26 ₹6,480.05 +1.44% 172
06/11/26 ₹6,387.90 +1.48% 2,792
05/11/26 ₹6,294.90 -1.10% 180
04/11/26 ₹6,365.10 +0.39% 172
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. ASTRAZEN Stock